Avian influenza prevention at the source
Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Search
Meet our team
Meet our team
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
The first liquid solution for hypertension in cats
Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
GastroGard the first imported equine drug in China
GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Big hearts united to help animals in Ukraine
Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.
European Metacam® indication expanded to guinea pigs
Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
Investment of 65 million euro in avian vaccines in France
Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
H5N1: Bird flu again. What’s different now?
H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
LastMile increases access to veterinary care in Africa
Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Partnering
Partnering
European Commission decision for Pradaxa® in children with VTE
Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age
Effect_of_Tiotropium_and_Salmeterol_in_COPD_Patients_With .pdf
ischaemic_stroke_protection_as_treatment_priority_for_patients_with_atrial_fibrillation.pdf
Caramelised_Figs_with_Rocket_and_Avocado.pdf
Your Guide to Partnering with Us
live_well_with_gpp_infographic.pdf
Live well with Generalized Pustular Psoriasis (GPP)
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.